Mai-Britt Zocca
Gründer bei IO BIOTECH, INC.
Vermögen: 75 486 $ am 31.05.2024
Aktive Positionen von Mai-Britt Zocca
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
IO BIOTECH, INC. | Direktor/Vorstandsmitglied | 01.01.2015 | - |
Vorstandsvorsitzender | 01.01.2015 | - | |
Gründer | 01.12.2014 | - | |
Präsident | 01.01.2015 | - | |
Finanzdirektor/CFO | 09.05.2022 | 15.10.2022 | |
Cobis A/S
Cobis A/S Miscellaneous Commercial ServicesCommercial Services Cobis A/S provides business support services. | Corporate Officer/Principal | - | - |
Entrepreneurial Learning Lab | Corporate Officer/Principal | - | - |
IO Biotech ApS
IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Vorstandsvorsitzender | - | - |
Finanzdirektor/CFO | 09.05.2022 | - | |
Gründer | - | - | |
Präsident | - | - | |
Dansk Biotek
Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | Direktor/Vorstandsmitglied | 01.05.2019 | - |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | Direktor/Vorstandsmitglied | 08.06.2020 | - |
Karriereverlauf von Mai-Britt Zocca
Ehemalige bekannte Positionen von Mai-Britt Zocca
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
OncoNOx ApS
OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | Direktor/Vorstandsmitglied | 01.07.2011 | 01.05.2019 |
Vorstandsvorsitzender | 01.07.2011 | 01.05.2019 | |
Gründer | 01.01.2011 | 01.05.2019 | |
LevOss ApS
LevOss ApS BiotechnologyHealth Technology LevOss ApS provides implant device for treatment of musculoskeletal. Its technology is based on mechanotransduction for tissue regeneration. The firm provides solutions for the treatment of bone defects. The company was founded by Jens Vinge Nygaard, Flemming Besenbacher, Cody Bünger, and Lea Bjerre Hokland and is headquartered in Copenhagen, Denmark. | Vorstandsvorsitzender | 01.01.2012 | 01.01.2017 |
Renovaro Biosciences Denmark ApS
Renovaro Biosciences Denmark ApS Miscellaneous Commercial ServicesCommercial Services Dandrit Biotech A/S conducts clinical research, trading, and manufacturing for the pharmaceutical industry. It focuses on research and development of medicines. The company was founded on April 1, 2001 and is headquartered in Hørsholm, Denmark. | Vorstandsvorsitzender | 01.07.2007 | 01.12.2010 |
░░░░░░░░░░ ░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░░░░ ░░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Ausbildung von Mai-Britt Zocca
University of Copenhagen | Doctorate Degree |
Statistik
International
Dänemark | 13 |
Finnland | 2 |
Operativ
Corporate Officer/Principal | 6 |
Chief Executive Officer | 5 |
Director/Board Member | 4 |
Sektoral
Health Technology | 6 |
Commercial Services | 4 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
IO BIOTECH, INC. | Health Technology |
Private Unternehmen | 10 |
---|---|
Symbion A/S
Symbion A/S General GovernmentGovernment Symbion A/S provides office communities, meeting facilities, conference facilities, business development and capital for start-up companies. The company was founded in 1986 and is headquartered in Copenhagen, Denmark. | Government |
Dansk Biotek
Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | Commercial Services |
Copenhagen Business Center | |
OncoNOx ApS
OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
Renovaro Biosciences Denmark ApS
Renovaro Biosciences Denmark ApS Miscellaneous Commercial ServicesCommercial Services Dandrit Biotech A/S conducts clinical research, trading, and manufacturing for the pharmaceutical industry. It focuses on research and development of medicines. The company was founded on April 1, 2001 and is headquartered in Hørsholm, Denmark. | Commercial Services |
LevOss ApS
LevOss ApS BiotechnologyHealth Technology LevOss ApS provides implant device for treatment of musculoskeletal. Its technology is based on mechanotransduction for tissue regeneration. The firm provides solutions for the treatment of bone defects. The company was founded by Jens Vinge Nygaard, Flemming Besenbacher, Cody Bünger, and Lea Bjerre Hokland and is headquartered in Copenhagen, Denmark. | Health Technology |
Entrepreneurial Learning Lab | |
IO Biotech ApS
IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Health Technology |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | Health Technology |
Cobis A/S
Cobis A/S Miscellaneous Commercial ServicesCommercial Services Cobis A/S provides business support services. | Commercial Services |
- Börse
- Insiders
- Mai-Britt Zocca
- Erfahrung